Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
547 stopped studies mapped to Malignant Nervous System Neoplasm and descendants · 90% state a reason
Over the 547 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02754362 | A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With… | Phase 2 | withdrawn | Apr 28, 2016 | NYU Langone Health | Due to personnel changes / departure of Dr. Chi. | Other (stated, no rule matched) |
| NCT02684071 | Phase II Study of Intraventricular Methotrexate in Children With Recurrent or Progressive… | Phase 2 | terminated | Feb 17, 2016 | Nicklaus Children's Hospital f/k/a Miami Children's Hospital | Lack of additional funding; patients (3) no longer receiving intervention. | Funding |
| NCT02465528 | Ceritinib Rare Indications Study in ALK+ Tumors | Phase 2 | terminated | Jun 8, 2015 | Novartis Pharmaceuticals | not stated | Not stated |
| NCT00428272 | HGS-ETR2 to Treat Children With Solid Tumors | Phase 1 | terminated | Jan 29, 2007 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01117155 | A Pilot Study Evaluating 18F-L-Thymidine (FLT) PET Imaging in Children With Gliomas | — | withdrawn | May 5, 2010 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00031538 | Genetic Analysis of Brain Tumors | — | terminated | Mar 7, 2002 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01251913 | A Pilot Study of Inpatient Hospice With Procurement of Brain Tumor Tissue on Expiration… | — | terminated | Dec 2, 2010 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT04051047 | Gemcitabine in Newly-Diagnosed Diffuse Midline Glioma | Early Phase 1 | withdrawn | Aug 9, 2019 | University of Michigan Rogel Cancer Center | Withdrawn by Principal Investigator | Investigator |
| NCT03843814 | Pilot Study Using Amide Proton Transfer Magnetic Resonance Imaging Distinguishing Glioma | N/A | terminated | Feb 18, 2019 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Imaging results were not sufficient or of good quality; therefore, we will not move further with… | Other (stated, no rule matched) |
| NCT00984438 | Surgery With Implantable Biodegradable Carmustine (BCNU) Wafer Followed by Chemo for… | Phase 1 / Phase 2 | withdrawn | Sep 25, 2009 | University of Cincinnati | No accrual | Enrollment / accrual |
| NCT01747876 | Study of Safety and Efficacy in Patients With Malignant Rhabdoid Tumors (MRT) and… | Phase 1 | terminated | Dec 12, 2012 | Novartis Pharmaceuticals | Lack of efficacy caused enrollment to be stopped at the end of dose escalation | Efficacy / futility |
| NCT02692898 | Biomarker Analysis of Central Nervous System Tumors | — | terminated | Feb 26, 2016 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00651716 | T Cells in Predicting Acute Graft-Versus-Host Disease in Patients Undergoing Donor Stem… | — | terminated | Apr 3, 2008 | Vanderbilt-Ingram Cancer Center | Funding unavailable | Funding |
| NCT01183884 | 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of Second or Greater… | Phase 2 | terminated | Aug 18, 2010 | Memorial Sloan Kettering Cancer Center | Low participant accrual | Enrollment / accrual |
| NCT02177773 | GA-68 DOTA-TOC of Somatostatin Positive Malignancies(DOTA-TOC) | Phase 1 / Phase 2 | terminated | Jun 30, 2014 | University of California, San Francisco | FDA approved agent for this indication during enrollment | Enrollment / accrual |
| NCT00035373 | Eligibility Screening of Patients With Central Nervous System Tumors for the National… | — | terminated | May 3, 2002 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT02689336 | Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory… | Phase 2 | withdrawn | Feb 23, 2016 | Washington University School of Medicine | Could not recruit any participants | Enrollment / accrual |
| NCT01182350 | Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG) | Phase 2 | terminated | Aug 16, 2010 | Karen D. Wright MD | Per design: Stop if fewer than 3 cohorts by molecular classification were with 10 participants or… | Enrollment / accrual |
| NCT01065805 | A Study to Demonstrate the Safety and Preliminary Efficacy of 18F-FLT in Patients With… | Phase 1 / Phase 2 | terminated | Feb 9, 2010 | AHS Cancer Control Alberta | Retirement of former Qualified Investigator and lack of resources to complete study | Investigator |
| NCT01014767 | Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid… | Phase 3 | terminated | Nov 17, 2009 | Tufts Medical Center | PI departure from coordinating institution | Other (stated, no rule matched) |
| NCT03632317 | A Study of Panobinostat in Combination With Everolimus for Children and Young Adults With… | Phase 2 | withdrawn | Aug 15, 2018 | University of Michigan Rogel Cancer Center | low accrual | Enrollment / accrual |
| NCT03480867 | Pre-operative RT and TMZ in Patients With Newly Diagnosed GBM Diagnosed Glioblastoma. A…(PARADIGMA) | Phase 1 | withdrawn | Mar 29, 2018 | McGill University Health Centre/Research Institute of the McGill University Health Centre | competing study was opened by the surgeon after this trial was opened | Other (stated, no rule matched) |
| NCT03246113 | Tolerability of Cannabis in Patients Receiving Concurrent Chemoradiation for Glioblastoma | Phase 1 | terminated | Aug 11, 2017 | New York State Psychiatric Institute | Lack of subject interest due to study design | Other (stated, no rule matched) |
| NCT02693171 | Post-Marketing Assessment of Immunogenicity and Safety of Unituxin® in High-Risk… | — | terminated | Feb 26, 2016 | United Therapeutics | Sponsor decision | Sponsor / business decision |
| NCT00539500 | Autologous Stem Cell Rescue With CD133+ Selected Cells in High-Risk Neuroblastoma | Phase 2 / Phase 3 | terminated | Oct 4, 2007 | M.D. Anderson Cancer Center | Slow Accrual. | Enrollment / accrual |
| NCT04002804 | Immunotherapy With Autologous Tumor Lysate-Loaded Dendritic Cells In Patients With…(Dendr2) | Phase 1 | terminated | Jul 1, 2019 | Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta | Temozolomide does not favour immune response; secondary GBM to be excluded | Other (stated, no rule matched) |
| NCT01159067 | Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and… | Phase 2 | terminated | Jul 9, 2010 | City of Hope Medical Center | Low enrollment | Enrollment / accrual |
| NCT00645385 | Examination of Changes on Magnetic Resonance Imaging (MRI) and Magnetic Resonance…(Gliadel-MRS) | — | withdrawn | Mar 27, 2008 | Weill Medical College of Cornell University | not stated | Not stated |
| NCT01601184 | Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in… | Phase 1 / Phase 2 | terminated | May 17, 2012 | Centre Leon Berard | The number of successes is not reached at the end of first stage of the phase II. The study is… | Other (stated, no rule matched) |
| NCT00031590 | Low-Dose Radiation and Combination Chemotherapy Following Surgery in Children With Newly… | Phase 2 | terminated | Jan 27, 2003 | Children's Hospital of Philadelphia | The study was terminated prematurely due to slow accrual. | Enrollment / accrual |
| NCT03558750 | Rituximab, Lenalidomide, and Nivolumab in Treating Participants With Relapsed or… | Phase 1 | terminated | Jun 15, 2018 | Vanderbilt-Ingram Cancer Center | Low accrual | Enrollment / accrual |
| NCT02395692 | Methoxyamine and Temozolomide in Treating Patients With Recurrent Glioblastoma | Phase 2 | terminated | Mar 24, 2015 | National Cancer Institute (NCI) | Pre-specified response criteria not met to proceed to next stage of study. | Other (stated, no rule matched) |
| NCT00801931 | Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders | Phase 1 / Phase 2 | terminated | Dec 4, 2008 | Columbia University | Poor accrual | Enrollment / accrual |
| NCT03403803 | Prognosis and Therapeutic Biomarkers for Glioblastoma Patients | — | terminated | Jan 19, 2018 | Baylor Research Institute | Were not able to meet enrollment goal due to inclusion/exclusion criteria | Enrollment / accrual |
| NCT02557854 | HIFU Hyperthermia With Liposomal Doxorubicin (DOXIL) for Relapsed or Refractory Pediatric… | Phase 1 | withdrawn | Sep 23, 2015 | Theodore Laetsch | Lack of enrollment | Enrollment / accrual |
| NCT03176160 | LITT Palliative Treatment for Patients With Malignant Gliomas | — | withdrawn | Jun 5, 2017 | Duke University | Failure to enroll | Enrollment / accrual |
| NCT02213536 | Investigating the Efficacy of Hair Sparing Radiotherapy Treatment to the Whole Brain.(SPARE) | — | terminated | Aug 11, 2014 | HCA International Limited | Poor recruitment and follow up | Enrollment / accrual |
| NCT01186406 | Gliadel, XRT, Temodar, Avastin Followed by Avastin, Temodar for Newly Diagnosed… | Phase 2 | terminated | Aug 23, 2010 | Duke University | Study ended early due to toxicity | Safety / toxicity |
| NCT01044966 | A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With… | Phase 1 / Phase 2 | terminated | Jan 8, 2010 | Medical University of South Carolina | The study was terminated due to lack of adequate patient enrollment into trial. | Enrollment / accrual |
| NCT01048060 | Consent for Obtaining Additional Bone Marrow Specimens at Time of Diagnostic Bone Marrow… | — | terminated | Jan 13, 2010 | Stanford University | Business Decision | Sponsor / business decision |
| NCT02796729 | CEST- Glucose Enhanced MRI for Metastatic Brain Tumours | Phase 2 | terminated | Jun 13, 2016 | British Columbia Cancer Agency | Not enough enrollment | Enrollment / accrual |
| NCT03293888 | Spectral Analysis Probe to Identify Glioblastoma Cells | — | terminated | Sep 26, 2017 | University of Oklahoma | PI Relocation | Other (stated, no rule matched) |
| NCT01432171 | Lacosamide in Preventing Seizures in Participants With Malignant Glioma | N/A | terminated | Sep 12, 2011 | M.D. Anderson Cancer Center | not stated | Not stated |
| NCT01293539 | Intra-arterial Chemotherapy for the Treatment of Intraocular Retinoblastoma | Phase 2 | terminated | Feb 10, 2011 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | IAC is now recognized as part of standard of care treatment options in the US. | Other (stated, no rule matched) |
| NCT03120000 | PQR309 in Phase 2 in Patients With Relapsed or Refractory Primary Central Nervous System… | Phase 2 | withdrawn | Apr 19, 2017 | PIQUR Therapeutics AG | Withdrawn | Other (stated, no rule matched) |
| NCT00734526 | Phase I Portion of Phase I/II Sorafenib With Radiation and Temozolomide in Newly… | Phase 1 | terminated | Aug 14, 2008 | M.D. Anderson Cancer Center | not stated | Not stated |
| NCT00895960 | Dasatinib Plus Radiation Therapy/Temozolomide in Newly-Diagnosed Glioblastoma | Phase 1 | terminated | May 11, 2009 | M.D. Anderson Cancer Center | Sponsor withdrew support; Study did not progress to Phase II. | Other (stated, no rule matched) |
| NCT02850744 | Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamic Effects of… | Phase 2 | terminated | Aug 1, 2016 | PIQUR Therapeutics AG | not stated | Not stated |
| NCT03212807 | Study Of Durvalumab and Lenalidomide In R/R EBV Associated DLBCL Subtypes, Primary CNS…(DuRIANS) | Phase 2 | withdrawn | Jul 11, 2017 | Singapore General Hospital | FDA Hold for Combination Studies using Imids and PD1/PDL1 Compounds | Other (stated, no rule matched) |
| NCT00960063 | A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment… | Phase 1 | terminated | Aug 17, 2009 | Merck Sharp & Dohme LLC | Study was terminated for business reasons. | Sponsor / business decision |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jan 13, 2020source: clinicaltrials